Cetrelimab is used to block the interaction between PD-1 and its ligands PD-L1/PD-L2, thereby enhancing T-cell activation; stimulating peripheral T cells to increase cytokine production (including IFN-γ, IL-2, and TNF-α); and inhibiting tumor growth in vivo.